GSK shipped its final batch of Cervarix at the end of August, and has announced it is pulling the vaccine because of “very low market demand.” The vaccine generated just £3m of revenues in the US for GSK last year.
When the two vaccines were launched, drug industry analysts were forecasting annual sales of up to $10bn, but safety concerns have dampened the take-up among teenage girls, and they have achieved just a 40 per cent coverage of the market.
The CDC is increasing the dosage that must be given from one shot to two, after a committee recommended the new schedule and CDC director Tom Frieden immediately sanctioned the suggestion. The move is being supported by a new advertising campaign that is urging parents to have their teenage daughters vaccinated.
Bryan Hubbard
What do you think? Start a conversation over on the... WDDTY Community
Great news! Discounts are available based on your cart total. Check the details below:
